Drug details

Zynteglo (betibeglogene autotemcel suspension for iv infusion)

type of Clotting Factors, Gene Therapy

Zynteglo (betibeglogene autotemcel) is an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of adult and pediatric patients with β-thalassemia who require regular red blood cell (RBC) transfusions.

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• rash,
• fever,
• confusion,
• weight gain,
• fatigue,
• fainting,
• overactive reflexes,
• loss of consciousness,
• seizures, and
• problems with coordination,
• memory loss,
• delirium,
• any bleeding that may not stop,
• pulmonary edema,
• abnormal liver and kidney function,
• altered level of consciousness,
• inability to speak or understand what is being said to you,
• inability to concentrate,
• slowness in activity,
• muscle contractions or spasms,
• flapping hand tremor,
• changes in your personality,
• rapid involuntary eye movement,
• abnormal blood counts